The Drive toward Regulatory Harmonization: What is Harmonization and How Will it Impact the Global Development of New Drugs?

Abstract

A great deal of discussion is heard about regulatory harmonization and efforts to shorten the drug submission regulatory review process. This article provides a historical perspective of the International Conference on Harmonization (ICH), its organizational structure, objectives, the five-step process, status of ICH guidelines, and recent progress. It also examines other “harmonization” initiatives such as the Declaration of Helsinki, World Health Organization (WHO), Council for International Organizations of Medical Sciences I (CIOMS I), CIOMSII, International Standards Organization (ISO) 9000, and European Union (EU) directives and regulations related to medicinal products. As a consequence of the growing body of regulations that have expanded the drug development process, it is appropriate to reevaluate drug development information needs and consider necessary changes in the management of the process to improve the quality of submissions and to reduce the global time to market.

Keywords

Harmonization ICH Quality Safety Efficacy WHO CIOMS Regulations Drug development information Global

Get full access to this article

View all access options for this article.

References

ICH 1. November 5–7, 1991.

ICH 2. October 27–29, 1993.

EFPIA News. October 1, 1992.

Council Regulation (EEC) No. 2309/93 of July 22, 1993.

Steps in the ICH Process for Harmonization of Guidelines ICH 3103. March 1994.

O'Donnell

Controversy over Clinical Study Reports. App Clin Trials. December 1993; 20–23.

O'Donnell

GCP-A Mosaic of Many Parts. App Clin Trials. May 1994; 28–32.

Ungar

Good Clinical Practices: Principles and Application of the European Community Note for Guidance. Drug Inf J. 1994;28: 339–348.

WHO Guidelines for Good Clinical Practice (GCP) For Trials or Pharmaceutical Products. November 1993.

10.

Edwards

The WHO Data Base I. Drug Inf J. 1992;26:477–480.

11.

Johnson

Dreis

Biriell

The WHO and FDA Adverse Drug Experience Reporting Databases: A US Perspective. 1991;3:655–672.

12.

Edwards

Lindquist

The WHO Data Base II. Drug Inf J. 1992;26:481–486.

13.

Gordon

Petrick

Worldwide Regulations for Manufacturers on Clinical Safety Surveillance of Drugs. Drug Inf J. 1992;26:1–15.

14.

International Reporting of Periodic Drug-Safety Update Summaries. CIOMS, Geneva, 1992.

15.

ISO 9000 International Standards for Quality Management; ISO Central Secretariat, Geneva, Switzerland.

16.

Lynch

Schwemer

ISO 9000 Policy Implications for FDA—Taking the Pulse or Increasing Global Use of the ISO Series of Uniform Quality Standards by FDA Regulated Industries. Regul Aff. 1993;5:1–40.

17.

Donnelly

European Community Registration Procedures. Regul Aff. 1993;5:473–512.

18.

Burstall

The Transparency Directive —Is It Working?

Pharmaco Econ. 1992;1(suppl. 1): 1–8.

19.

Ansell

“Hypothetical Possibility—European Style.”

Pharma Exec. February 1994; 60.

20.

Turner

Inspections in the European Community 1993 Onwards. Regul Aff. 1993;5:513–522.

21.

Meyer

The Future GMP inspection system (inside and outside the European Community): What does subsidiarity really mean?

Drug Inf J. 1994;28(4).

22.

Phillip

Weihrauch

Multinational Drug Development and Clinical Research: A Bird's Eye View of Principles and Practice. Drug Inf J. 1993;27:1121–1132.